Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Prostate Retrieve available abstracts of 231 articles: HTML format Text format

Single Articles

January 2019
1. LIU Y, Wu X, Jiang H
   Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
   Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
   PubMed     Text format     Abstract available
   
   
   
2. FAN L, Yang Y, Chi C, Ma X, et al
   Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
   Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
   PubMed     Text format     Abstract available
   
   
   
3. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
   Identification of targets for prostate cancer immunotherapy.
   Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
   PubMed     Text format     Abstract available
   
   
   
4. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
   HOXA10 expression profiling in prostate cancer.
   Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
   PubMed     Text format     Abstract available
   
   
   
5. ZHAO M, Qi M, Li X, Hu J, et al
   CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
   Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
   PubMed     Text format     Abstract available
   
   
   
6. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
   Salicylate enhances the response of prostate cancer to radiotherapy.
   Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
   PubMed     Text format     Abstract available
   
   
   December 2018
7. TSUMURA H, Ishiyama H, Tabata KI, Sekiguchi A, et al
   Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
   Prostate. 2018 Dec 26. doi: 10.1002/pros.23757.
   PubMed     Text format     Abstract available
   
   
   
8. MATEUS PAM, Kido LA, Silva RS, Cagnon VHA, et al
   Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
   Prostate. 2018 Dec 25. doi: 10.1002/pros.23758.
   PubMed     Text format     Abstract available
   
   
   
9. DONADIO JLS, Liu L, Freeman VL, Ekoue DN, et al
   Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.
   Prostate. 2018 Dec 23. doi: 10.1002/pros.23752.
   PubMed     Text format     Abstract available
   
   
   
10. IWAMOTO H, Izumi K, Natsagdorj A, Naito R, et al
    Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells.
    Prostate. 2018 Dec 19. doi: 10.1002/pros.23753.
    PubMed     Text format     Abstract available
    
    
    
11. JOHNG D, Torga G, Ewing CM, Jin K, et al
    HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Prostate. 2018 Dec 17. doi: 10.1002/pros.23747.
    PubMed     Text format     Abstract available
    
    
    
12. BARBAUD M, Frindel M, Ferrer L, Le Thiec M, et al
    68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Prostate. 2018 Dec 14. doi: 10.1002/pros.23751.
    PubMed     Text format     Abstract available
    
    
    
13. ADAMO H, Hammarsten P, Hagglof C, Dahl Scherdin T, et al
    Prostate cancer induces C/EBPbeta expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
    Prostate. 2018 Dec 11. doi: 10.1002/pros.23749.
    PubMed     Text format     Abstract available
    
    
    
14. ZEDAN AH, Hansen TF, Assenholt J, Madsen JS, et al
    Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
    Prostate. 2018 Dec 9. doi: 10.1002/pros.23748.
    PubMed     Text format     Abstract available
    
    
    November 2018
15. ERLANDSSON A, Carlsson J, Lundholm M, Falt A, et al
    M2 macrophages and regulatory T cells in lethal prostate cancer.
    Prostate. 2018 Nov 30. doi: 10.1002/pros.23742.
    PubMed     Text format     Abstract available
    
    
    
16. MAJERA D, Skrott Z, Bouchal J, Bartkova J, et al
    Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
    Prostate. 2018 Nov 29. doi: 10.1002/pros.23741.
    PubMed     Text format     Abstract available
    
    
    
17. KRUEGER TE, Thorek DLJ, Meeker AK, Isaacs JT, et al
    Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23738.
    PubMed     Text format     Abstract available
    
    
    
18. COHEN M, Amir S, Golan M, Ben-Neriah Y, et al
    beta-TrCP upregulates HIF-1 in prostate cancer cells.
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23746.
    PubMed     Text format     Abstract available
    
    
    
19. MIYAKE M, Tanaka N, Hori S, Ohnishi S, et al
    Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23740.
    PubMed     Text format     Abstract available
    
    
    
20. GIRI VN, Hegarty SE, Hyatt C, O'Leary E, et al
    Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23739.
    PubMed     Text format     Abstract available
    
    
    
21. ALANEE S, Holland B, Clemons J, Dynda D, et al
    Death due to sepsis in patients diagnosed with prostate cancer.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23735.
    PubMed     Text format     Abstract available
    
    
    
22. GIULIANELLI R, Nardoni S, Bruzzese D, Falavolti C, et al
    Urotensin II receptor expression in prostate cancer patients: A new possible marker.
    Prostate. 2018 Nov 8. doi: 10.1002/pros.23734.
    PubMed     Text format     Abstract available
    
    
    October 2018
23. MIYAHIRA AK, Den RB, Carlo MI, de Leeuw R, et al
    Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2018 Oct 31. doi: 10.1002/pros.23729.
    PubMed     Text format     Abstract available
    
    
    
24. LAVOIE JM, Zou K, Khalaf D, Eigl BJ, et al
    Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Prostate. 2018 Oct 28. doi: 10.1002/pros.23733.
    PubMed     Text format     Abstract available
    
    
    
25. SUER I, Guzel E, Karatas OF, Creighton CJ, et al
    MicroRNAs as prognostic markers in prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23731.
    PubMed     Text format     Abstract available
    
    
    
26. ESKRA JN, Schlicht MJ, Bosland MC
    Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23727.
    PubMed     Text format     Abstract available
    
    
    
27. KRANZBUHLER B, Salemi S, Mortezavi A, Sulser T, et al
    Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23725.
    PubMed     Text format     Abstract available
    
    
    
28. SEKINO Y, Oue N, Mukai S, Shigematsu Y, et al
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2018 Oct 16. doi: 10.1002/pros.23728.
    PubMed     Text format     Abstract available
    
    
    
29. ERYILMAZ IE, Aytac Vuruskan B, Kaygisiz O, Egeli U, et al
    RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Prostate. 2018 Oct 7. doi: 10.1002/pros.23724.
    PubMed     Text format     Abstract available
    
    
    
30. WADOSKY KM, Shourideh M, Goodrich DW, Koochekpour S, et al
    Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.
    Prostate. 2018 Oct 2. doi: 10.1002/pros.23719.
    PubMed     Text format     Abstract available
    
    
    September 2018
31. JAIN S, Dash P, Minz AP, Satpathi S, et al
    Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-kappaB activation and recurrent dexamethasone administration fails to suppress it in vivo.
    Prostate. 2018 Sep 27. doi: 10.1002/pros.23722.
    PubMed     Text format     Abstract available
    
    
    
32. WANG J, Lu Z, Wu C, Li Y, et al
    Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23711.
    PubMed     Text format     Abstract available
    
    
    
33. ROBERTO D, Klotz LH, Venkateswaran V
    Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23720.
    PubMed     Text format     Abstract available
    
    
    
34. LIU J, Ding D, Jiang Z, Du T, et al
    Long non-coding RNA CCAT1/miR-148a/PKCzeta prevents cell migration of prostate cancer by altering macrophage polarization.
    Prostate. 2018 Sep 16. doi: 10.1002/pros.23716.
    PubMed     Text format     Abstract available
    
    
    
35. CHEN Z, Jiang Q, Zhu P, Chen Y, et al
    NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Prostate. 2018 Sep 3. doi: 10.1002/pros.23709.
    PubMed     Text format     Abstract available
    
    
    
36. DUGUE PA, Dowty JG, Joo JE, Wong EM, et al
    Heritable methylation marks associated with breast and prostate cancer risk.
    Prostate. 2018;78:962-969.
    PubMed     Text format     Abstract available
    
    
    
37. VAN DUIJN PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, et al
    Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    Prostate. 2018;78:1013-1023.
    PubMed     Text format     Abstract available
    
    
    August 2018
38. LI Y, Zhang Q, Lovnicki J, Chen R, et al
    SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23715.
    PubMed     Text format     Abstract available
    
    
    
39. PALLER C, Pu H, Begemann DE, Wade CA, et al
    TGF-beta receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23708.
    PubMed     Text format     Abstract available
    
    
    
40. XIE W, Stopsack KH, Drouin SJ, Fu H, et al
    Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23712.
    PubMed     Text format     Abstract available
    
    
    
41. TOMMASI S, Pilato B, Carella C, Lasorella A, et al
    Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23710.
    PubMed     Text format     Abstract available
    
    
    
42. ALANEE S, El-Zawahry A, Dynda D, Dabaja A, et al
    A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.
    Prostate. 2018 Aug 16. doi: 10.1002/pros.23713.
    PubMed     Text format     Abstract available
    
    
    
43. WEISSENRIEDER JS, Reilly JE, Neighbors JD, Hohl RJ, et al
    Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Prostate. 2018 Aug 14. doi: 10.1002/pros.23707.
    PubMed     Text format     Abstract available
    
    
    
44. HUANG W, Su X, Yan W, Kong Z, et al
    Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
    Prostate. 2018 Aug 13. doi: 10.1002/pros.23700.
    PubMed     Text format     Abstract available
    
    
    
45. CUI F, Hu J, Ning S, Tan J, et al
    Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
    Prostate. 2018 Aug 10. doi: 10.1002/pros.23703.
    PubMed     Text format     Abstract available
    
    
    
46. GEVARIYA N, Besancon M, Robitaille K, Picard V, et al
    Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23706.
    PubMed     Text format     Abstract available
    
    
    
47. NAVONE NM, van Weerden WM, Vessella RL, Williams ED, et al
    Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23701.
    PubMed     Text format     Abstract available
    
    
    July 2018
48. CHAKRAVARTHI BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, et al
    Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23704.
    PubMed     Text format     Abstract available
    
    
    
49. KOIDE H, Kimura T, Inaba H, Sato S, et al
    Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23705.
    PubMed     Text format     Abstract available
    
    
    
50. WU Y, Yu H, Zheng SL, Feng B, et al
    Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
    Prostate. 2018 Jul 24. doi: 10.1002/pros.23697.
    PubMed     Text format     Abstract available
    
    
    
51. LIU C, Zhu Y, Su H, Xu X, et al
    Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23696.
    PubMed     Text format     Abstract available
    
    
    
52. YAMAKAWA T, Waer C, Itakura K
    AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23699.
    PubMed     Text format     Abstract available
    
    
    
53. ROOT A, Ebhardt HA
    A two-drug combination simulation study for metastatic castrate resistant prostate cancer.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23694.
    PubMed     Text format     Abstract available
    
    
    
54. YANG T, Jing Y, Dong J, Yu X, et al
    Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23695.
    PubMed     Text format     Abstract available
    
    
    
55. HE W, Li J
    Exendin-4 enhances radiation response of prostate cancer.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23687.
    PubMed     Text format     Abstract available
    
    
    
56. LI D, Tian G, Wang J, Zhao LY, et al
    Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23689.
    PubMed     Text format     Abstract available
    
    
    
57. DORAI T, Shah A, Summers F, Mathew R, et al
    NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23693.
    PubMed     Text format     Abstract available
    
    
    
58. TWEEDLE MF, Ding H, Drost WT, Dowell J, et al
    Development of an orthotopic canine prostate cancer model expressing human GRPr.
    Prostate. 2018 Jul 11. doi: 10.1002/pros.23686.
    PubMed     Text format     Abstract available
    
    
    
59. LIM DM, Gulati R, Aleshin-Guendel S, Gawne A, et al
    Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival.
    Prostate. 2018 Jul 10. doi: 10.1002/pros.23666.
    PubMed     Text format     Abstract available
    
    
    
60. ROGASCH JM, Cash H, Zschaeck S, Elezkurtaj S, et al
    Ga-68-PSMA PET/CT in treatment-naive patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
    Prostate. 2018 Jul 5. doi: 10.1002/pros.23685.
    PubMed     Text format     Abstract available
    
    
    June 2018
61. ZHAO S, Leonardson A, Geybels MS, McDaniel AS, et al
    A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.
    Prostate. 2018 Jun 28. doi: 10.1002/pros.23667.
    PubMed     Text format     Abstract available
    
    
    
62. COOK SF, Fiandalo MV, Watt DS, Wu Y, et al
    Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
    Prostate. 2018 Jun 25. doi: 10.1002/pros.23665.
    PubMed     Text format     Abstract available
    
    
    
63. HELFAND BT, Chen H, Fantus RJ, Conran CA, et al
    Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
    Prostate. 2018 Jun 19. doi: 10.1002/pros.23664.
    PubMed     Text format     Abstract available
    
    
    
64. BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
    Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
    PubMed     Text format     Abstract available
    
    
    
65. CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
    A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
    PubMed     Text format     Abstract available
    
    
    
66. CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
    Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
    Prostate. 2018;78:693-694.
    PubMed     Text format    
    
    
    May 2018
67. MIYAHIRA AK, Soule HR
    The 24th Annual Prostate Cancer Foundation scientific retreat report.
    Prostate. 2018 May 15. doi: 10.1002/pros.23651.
    PubMed     Text format     Abstract available
    
    
    
68. AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
    Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
    Prostate. 2018 May 15. doi: 10.1002/pros.23653.
    PubMed     Text format     Abstract available
    
    
    
69. JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
    Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Prostate. 2018 May 10. doi: 10.1002/pros.23647.
    PubMed     Text format     Abstract available
    
    
    
70. MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
    Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23648.
    PubMed     Text format     Abstract available
    
    
    
71. TINAY I, Tan M, Gui B, Werner L, et al
    Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23650.
    PubMed     Text format     Abstract available
    
    
    
72. ALLOTT EH, Farnan L, Steck SE, Song L, et al
    Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
    Prostate. 2018 May 1. doi: 10.1002/pros.23644.
    PubMed     Text format     Abstract available
    
    
    
73. MIYAHIRA AK, Pienta KJ, Morris MJ, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
    Prostate. 2018 May 1. doi: 10.1002/pros.23642.
    PubMed     Text format     Abstract available
    
    
    April 2018
74. ISHII K, Sasaki T, Iguchi K, Kajiwara S, et al
    Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23643.
    PubMed     Text format     Abstract available
    
    
    
75. FRANCINI E, Gray KP, Xie W, Shaw GK, et al
    Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23645.
    PubMed     Text format     Abstract available
    
    
    
76. BEYENE DA, Naab TJ, Kanarek NF, Apprey V, et al
    Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
    Prostate. 2018 Apr 22. doi: 10.1002/pros.23537.
    PubMed     Text format     Abstract available
    
    
    
77. BAYAT H, Narouie B, Ziaee SM, Mowla SJ, et al
    Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
    Prostate. 2018 Apr 19. doi: 10.1002/pros.23538.
    PubMed     Text format     Abstract available
    
    
    
78. MILLER EA, Pinsky PF, Black A, Andriole GL, et al
    Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Prostate. 2018 Apr 17. doi: 10.1002/pros.23540.
    PubMed     Text format     Abstract available
    
    
    
79. POMPE RS, Tilki D, Preisser F, Leyh-Bannurah SR, et al
    Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23519.
    PubMed     Text format     Abstract available
    
    
    
80. KOSTOVA MB, Brennen WN, Lopez D, Anthony L, et al
    PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23539.
    PubMed     Text format     Abstract available
    
    
    
81. GIRI VN, Obeid E, Hegarty SE, Gross L, et al
    Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
    Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
    PubMed     Text format     Abstract available
    
    
    
82. MORI K, Kimura T, Ito K, Onuma H, et al
    Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
    PubMed     Text format     Abstract available
    
    
    
83. BRATT O
    RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.
    PubMed     Text format    
    
    
    
84. KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
    Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
    PubMed     Text format     Abstract available
    
    
    
85. PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
    Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
    PubMed     Text format     Abstract available
    
    
    
86. PREISSER F, Bandini M, Graefen M, Tilki D, et al
    Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.
    PubMed     Text format    
    
    
    March 2018
87. GAO X, Mao YH, Xiao C, Li K, et al
    Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
    Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
    PubMed     Text format     Abstract available
    
    
    
88. BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
    Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
    PubMed     Text format     Abstract available
    
    
    
89. BRENNEN WN, Isaacs JT
    The what, when, and why of human prostate cancer xenografts.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
    PubMed     Text format     Abstract available
    
    
    
90. LINXWEILER J, Korbel C, Muller A, Hammer M, et al
    A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
    PubMed     Text format     Abstract available
    
    
    
91. AKINBOYE ES, Rogers OC, Isaacs JT
    2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
    PubMed     Text format     Abstract available
    
    
    
92. CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
    Exercise and prostate cancer: From basic science to clinical applications.
    Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
    PubMed     Text format     Abstract available
    
    
    
93. CHEN J, Oromendia C, Halpern JA, Ballman KV, et al
    National trends in management of localized prostate cancer: A population based analysis 2004-2013.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23496.
    PubMed     Text format     Abstract available
    
    
    
94. WANG Y, Xu H, Si L, Li Q, et al
    MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23468.
    PubMed     Text format     Abstract available
    
    
    
95. DAVID SN, Arnold Egloff SA, Goyal R, Clark PE, et al
    MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23506.
    PubMed     Text format     Abstract available
    
    
    
96. CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
    PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
    PubMed     Text format     Abstract available
    
    
    
97. KEAM SP, Gulati T, Gamell C, Caramia F, et al
    Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
    PubMed     Text format     Abstract available
    
    
    
98. HAYMAN J, Phillips R, Chen D, Perin J, et al
    Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
    PubMed     Text format     Abstract available
    
    
    
99. WU Y, Yu H, Zheng SL, Na R, et al
    A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
    PubMed     Text format     Abstract available
    
    
    
100. OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
     AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
     Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
     PubMed     Text format     Abstract available
     
     
     February 2018
101. COPELAND BT, Pal SK, Bolton EC, Jones JO, et al
     The androgen receptor malignancy shift in prostate cancer.
     Prostate. 2018 Feb 23. doi: 10.1002/pros.23497.
     PubMed     Text format     Abstract available
     
     
     
102. ITO K, Kimura T, Onuma H, Tabata R, et al
     Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
     Prostate. 2018 Feb 23. doi: 10.1002/pros.23493.
     PubMed     Text format     Abstract available
     
     
     
103. MACCINI MA, Westfall NJ, Van Bokhoven A, Lucia MS, et al
     The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
     Prostate. 2018 Feb 19. doi: 10.1002/pros.23495.
     PubMed     Text format     Abstract available
     
     
     
104. PREISSER F, Bandini M, Marchioni M, Nazzani S, et al
     Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
     Prostate. 2018 Feb 19. doi: 10.1002/pros.23491.
     PubMed     Text format     Abstract available
     
     
     
105. SHOU J, Zhang Q, Wang S, Zhang D, et al
     The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
     Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
     PubMed     Text format     Abstract available
     
     
     
106. DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
     Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
     Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
     PubMed     Text format     Abstract available
     
     
     
107. SILVA JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, et al
     Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration.
     Prostate. 2018;78:95-103.
     PubMed     Text format     Abstract available
     
     
     
108. RODRIGO MAM, Strmiska V, Horackova E, Buchtelova H, et al
     Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
     Prostate. 2018;78:104-112.
     PubMed     Text format     Abstract available
     
     
     
109. PAZIEWSKA A, Mikula M, Dabrowska M, Kulecka M, et al
     Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
     Prostate. 2018;78:178-185.
     PubMed     Text format     Abstract available
     
     
     January 2018
110. JIANG X, Huang Y, Liang X, Jiang F, et al
     Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23487.
     PubMed     Text format     Abstract available
     
     
     
111. KARLSSON T, Sundar R, Widmark A, Landstrom M, et al
     Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor beta (TGFbeta) signaling.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23489.
     PubMed     Text format     Abstract available
     
     
     
112. MCDONALD AC, Vira M, Shen J, Sanda M, et al
     Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23485.
     PubMed     Text format     Abstract available
     
     
     
113. WANG L, Kim D, Wise JTF, Shi X, et al
     p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
     PubMed     Text format     Abstract available
     
     
     
114. WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
     Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
     PubMed     Text format     Abstract available
     
     
     
115. ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
     Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
     PubMed     Text format     Abstract available
     
     
     
116. MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
     Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
     PubMed     Text format     Abstract available
     
     
     
117. DU Z, Lubmawa A, Gundell S, Wan P, et al
     Genetic risk of prostate cancer in ugandan men.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
     PubMed     Text format     Abstract available
     
     
     
118. BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
     Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
     PubMed     Text format     Abstract available
     
     
     
119. HUANG H, Wang Q, Du T, Lin C, et al
     Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
     PubMed     Text format     Abstract available
     
     
     
120. SU Z, Zhang M, Xu M, Li X, et al
     MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
     Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
     PubMed     Text format     Abstract available
     
     
     
121. KIMBROUGH-ALLAH MN, Millena AC, Khan SA
     Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
     Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
     PubMed     Text format     Abstract available
     
     
     
122. HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
     Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
     Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
     PubMed     Text format     Abstract available
     
     
     
123. XU L, Shen M, Chen X, Zhu R, et al
     Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
     Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
     PubMed     Text format     Abstract available
     
     
     
124. AZUMA T
     Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
     Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.
     PubMed     Text format    
     
     
     
125. ALBITAR M, Ma W, Lund L, Shahbaba B, et al
     Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
     Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
     PubMed     Text format     Abstract available
     
     
     
126. EKOUE DN, Ansong E, Liu L, Macias V, et al
     Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
     Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
     PubMed     Text format     Abstract available
     
     
     
127. LIN HM, Lee BY, Castillo L, Spielman C, et al
     Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
     Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
     PubMed     Text format     Abstract available
     
     
     
128. TYAGI P, Motley SS, Koyama T, Kashyap M, et al
     Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
     Prostate. 2018;78:17-24.
     PubMed     Text format     Abstract available
     
     
     December 2017
129. VAN DER TOOM EE, Groot VP, Glavaris SA, Gemenetzis G, et al
     Analogous detection of circulating tumor cells using the AccuCyte((R)) -CyteFinder((R)) system and ISET system in patients with locally advanced and metastatic prostate cancer.
     Prostate. 2017 Dec 29. doi: 10.1002/pros.23474.
     PubMed     Text format     Abstract available
     
     
     
130. FAN L, Wang R, Chi C, Cai W, et al
     Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
     Prostate. 2017 Dec 29. doi: 10.1002/pros.23465.
     PubMed     Text format     Abstract available
     
     
     
131. MCLEOD AB, Stice JP, Wardell SE, Alley HM, et al
     Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
     Prostate. 2017 Dec 15. doi: 10.1002/pros.23467.
     PubMed     Text format     Abstract available
     
     
     
132. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
     Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
     Prostate. 2017;77:1592-1600.
     PubMed     Text format     Abstract available
     
     
     
133. ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
     Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
     Prostate. 2017;77:1573-1582.
     PubMed     Text format     Abstract available
     
     
     
134. BAUER SR, Van Blarigan EL, Stampfer MJ, Chan JM, et al
     Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23457.
     PubMed     Text format     Abstract available
     
     
     
135. ANDO T, Nishiyama T, Takizawa I, Miyashiro Y, et al
     A carbon 21 steroidal metabolite from progestin, 20beta-hydroxy-5alpha-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23460.
     PubMed     Text format     Abstract available
     
     
     
136. FIANDALO MV, Wilton JH, Mantione KM, Wrzosek C, et al
     Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23459.
     PubMed     Text format     Abstract available
     
     
     November 2017
137. YAN G, Ru Y, Wu K, Yan F, et al
     GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
     Prostate. 2017 Nov 27. doi: 10.1002/pros.23461.
     PubMed     Text format     Abstract available
     
     
     
138. CHEN H, Ewing CM, Zheng S, Grindedaal EM, et al
     Genetic factors influencing prostate cancer risk in Norwegian men.
     Prostate. 2017 Nov 27. doi: 10.1002/pros.23453.
     PubMed     Text format     Abstract available
     
     
     
139. JOSHU CE, Peskoe SB, Heaphy CM, Kenfield SA, et al
     Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
     Prostate. 2017 Nov 22. doi: 10.1002/pros.23462.
     PubMed     Text format     Abstract available
     
     
     
140. TSUI KH, Chang YL, Feng TH, Hou CP, et al
     Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
     Prostate. 2017 Nov 22. doi: 10.1002/pros.23463.
     PubMed     Text format     Abstract available
     
     
     
141. FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
     Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
     Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
     PubMed     Text format     Abstract available
     
     
     
142. GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
     Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
     Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
     PubMed     Text format     Abstract available
     
     
     
143. KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
     Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
     Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
     PubMed     Text format     Abstract available
     
     
     
144. COARFA C, Florentin D, Putluri N, Ding Y, et al
     Influence of the neural microenvironment on prostate cancer.
     Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
     PubMed     Text format     Abstract available
     
     
     
145. TAT D, Kenfield SA, Cowan JE, Broering JM, et al
     Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
     PubMed     Text format     Abstract available
     
     
     
146. MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
     The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
     PubMed     Text format     Abstract available
     
     
     
147. CHENG HH, Plets M, Li H, Higano CS, et al
     Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
     PubMed     Text format     Abstract available
     
     
     
148. XIAO H, Wang J, Yan W, Cui Y, et al
     GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
     PubMed     Text format     Abstract available
     
     
     
149. SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
     99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
     PubMed     Text format     Abstract available
     
     
     
150. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
     FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
     PubMed     Text format     Abstract available
     
     
     
151. BONKHOFF H
     Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
     PubMed     Text format     Abstract available
     
     
     
152. KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
     Prognostic parameter for high risk prostate cancer patients at initial presentation.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
     PubMed     Text format     Abstract available
     
     
     
153. TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
     Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
     PubMed     Text format     Abstract available
     
     
     
154. NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
     The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
     Prostate. 2017;77:1539-1547.
     PubMed     Text format     Abstract available
     
     
     October 2017
155. STARK TW, Hensley PJ, Spear A, Pu H, et al
     Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
     Prostate. 2017 Oct 23. doi: 10.1002/pros.23435.
     PubMed     Text format     Abstract available
     
     
     
156. WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
     The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
     Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
     PubMed     Text format     Abstract available
     
     
     
157. LI E, Liu L, Li F, Luo L, et al
     PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
     Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
     PubMed     Text format     Abstract available
     
     
     
158. ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
     Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
     Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
     PubMed     Text format     Abstract available
     
     
     
159. SHI X, Peng Y, Du X, Liu H, et al
     Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.
     Prostate. 2017;77:1424-1437.
     PubMed     Text format     Abstract available
     
     
     
160. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
     Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
     Prostate. 2017;77:1383-1388.
     PubMed     Text format     Abstract available
     
     
     September 2017
161. BURDELSKI C, Shihada R, Hinsch A, Angerer A, et al
     High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
     Prostate. 2017 Sep 19. doi: 10.1002/pros.23431.
     PubMed     Text format     Abstract available
     
     
     
162. MIYAHIRA AK, Cheng HH, Abida W, Ellis L, et al
     Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
     Prostate. 2017 Sep 18. doi: 10.1002/pros.23424.
     PubMed     Text format     Abstract available
     
     
     
163. TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
     Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
     PubMed     Text format     Abstract available
     
     
     
164. KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
     Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
     PubMed     Text format     Abstract available
     
     
     
165. PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
     Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
     PubMed     Text format     Abstract available
     
     
     
166. STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
     Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
     Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
     PubMed     Text format     Abstract available
     
     
     
167. YANG CS, Melhuish TA, Spencer A, Ni L, et al
     The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
     Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
     PubMed     Text format     Abstract available
     
     
     
168. VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
     Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
     Prostate. 2017;77:1242-1250.
     PubMed     Text format     Abstract available
     
     
     August 2017
169. GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
     Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
     PubMed     Text format     Abstract available
     
     
     
170. SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
     Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
     PubMed     Text format     Abstract available
     
     
     
171. HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
     A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
     PubMed     Text format     Abstract available
     
     
     
172. SUH JH, Park JH, Lee C, Moon KC, et al
     Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
     PubMed     Text format     Abstract available
     
     
     
173. LIU L, Li E, Luo L, Zhao S, et al
     PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
     PubMed     Text format     Abstract available
     
     
     
174. MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
     Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
     PubMed     Text format     Abstract available
     
     
     
175. DONG B, Fan L, Wang Y, Chi C, et al
     Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
     Prostate. 2017 Aug 14. doi: 10.1002/pros.23397.
     PubMed     Text format     Abstract available
     
     
     
176. STRUSS WJ, Tan Z, Zachkani P, Moskalev I, et al
     Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
     Prostate. 2017 Aug 8. doi: 10.1002/pros.23395.
     PubMed     Text format     Abstract available
     
     
     
177. PALLER CJ, Cole AP, Partin AW, Carducci MA, et al
     Risk factors for metastatic prostate cancer: A sentinel event case series.
     Prostate. 2017 Aug 8. doi: 10.1002/pros.23396.
     PubMed     Text format     Abstract available
     
     
     
178. VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
     Epigenetic risk score improves prostate cancer risk assessment.
     Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
     PubMed     Text format     Abstract available
     
     
     
179. HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
     The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
     Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
     PubMed     Text format     Abstract available
     
     
     July 2017
180. FAN L, Wang X, Chi C, Wang Y, et al
     Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
     Prostate. 2017 Jul 28. doi: 10.1002/pros.23381.
     PubMed     Text format     Abstract available
     
     
     
181. SUN G, Huang R, Zhang X, Shen P, et al
     The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
     Prostate. 2017 Jul 27. doi: 10.1002/pros.23388.
     PubMed     Text format     Abstract available
     
     
     
182. SHARPE B, Alghezi DA, Cattermole C, Beresford M, et al
     A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
     Prostate. 2017 Jul 26. doi: 10.1002/pros.23391.
     PubMed     Text format     Abstract available
     
     
     
183. LIN X, Chen Z, Gao P, Gao Z, et al
     TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.
     Prostate. 2017 Jul 21. doi: 10.1002/pros.23387.
     PubMed     Text format     Abstract available
     
     
     
184. AI J, Tai PWL, Lu Y, Li J, et al
     Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23386.
     PubMed     Text format     Abstract available
     
     
     
185. TODENHOFER T, Hennenlotter J, Keller G, Neumann T, et al
     Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23384.
     PubMed     Text format     Abstract available
     
     
     
186. BREEN KJ, O'Neill A, Murphy L, Fan Y, et al
     Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23389.
     PubMed     Text format     Abstract available
     
     
     
187. CHEN H, Na R, Packiam VT, Conran CA, et al
     Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
     Prostate. 2017 Jul 2. doi: 10.1002/pros.23369.
     PubMed     Text format     Abstract available
     
     
     
188. DE BARI B, Stish B, Ball MW, Habboush Y, et al
     Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
     Prostate. 2017;77:1160-1166.
     PubMed     Text format     Abstract available
     
     
     
189. RODRIGUES TM, Mitre AI, da Silva LFF, Castilho LN, et al
     Periprostatic innervation: New issues based on segmental analysis of 10 human cadaver pelvic blocs.
     Prostate. 2017;77:1151-1159.
     PubMed     Text format     Abstract available
     
     
     
190. BOKHORST LP, Roobol MJ, Bangma CH, van Leenders GJ, et al
     Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
     Prostate. 2017;77:1137-1143.
     PubMed     Text format     Abstract available
     
     
     June 2017
191. LAWAL IO, Ankrah AO, Mokgoro NP, Vorster M, et al
     Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
     Prostate. 2017 Jun 26. doi: 10.1002/pros.23379.
     PubMed     Text format     Abstract available
     
     
     
192. CRUMBAKER M, Gurney H
     Dose considerations for anti-cancer drugs in metastatic prostate cancer.
     Prostate. 2017 Jun 26. doi: 10.1002/pros.23378.
     PubMed     Text format     Abstract available
     
     
     
193. HE C, Duan S, Dong L, Wang Y, et al
     Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
     Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
     PubMed     Text format     Abstract available
     
     
     
194. CAI B, Chen W, Pan Y, Chen H, et al
     Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
     Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
     PubMed     Text format     Abstract available
     
     
     
195. XU Y, Qin S, An T, Tang Y, et al
     MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
     Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
     PubMed     Text format     Abstract available
     
     
     
196. ZHAO R, Sun F, Bei X, Wang X, et al
     Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
     Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
     PubMed     Text format     Abstract available
     
     
     
197. ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
     MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
     Prostate. 2017;77:1020-1028.
     PubMed     Text format     Abstract available
     
     
     
198. GONZAGA ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, et al
     Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.
     Prostate. 2017;77:937-948.
     PubMed     Text format     Abstract available
     
     
     
199. AJIBOYE AS, Esopi D, Yegnasubramanian S, Denmeade SR, et al
     Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
     Prostate. 2017;77:829-837.
     PubMed     Text format     Abstract available
     
     
     
200. KIDO LA, Montico F, Vendramini-Costa DB, Pilli RA, et al
     Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
     Prostate. 2017;77:838-848.
     PubMed     Text format     Abstract available
     
     
     
201. SHARIF A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, et al
     The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
     Prostate. 2017;77:824-828.
     PubMed     Text format     Abstract available
     
     
     May 2017
202. MORI K, Kimura T, Onuma H, Kimura S, et al
     Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
     Prostate. 2017 May 30. doi: 10.1002/pros.23373.
     PubMed     Text format     Abstract available
     
     
     
203. KIM Y, Park SE, Moon JW, Kim BM, et al
     Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
     Prostate. 2017 May 30. doi: 10.1002/pros.23370.
     PubMed     Text format     Abstract available
     
     
     
204. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
     Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
     Prostate. 2017 May 26. doi: 10.1002/pros.23364.
     PubMed     Text format     Abstract available
     
     
     
205. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
     Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
     Prostate. 2017 May 24. doi: 10.1002/pros.23368.
     PubMed     Text format     Abstract available
     
     
     
206. MIYAHIRA AK, Soule HR
     The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
     Prostate. 2017 May 14. doi: 10.1002/pros.23366.
     PubMed     Text format     Abstract available
     
     
     
207. NOVAKOVA Z, Foss CA, Copeland BT, Morath V, et al
     Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
     Prostate. 2017;77:749-764.
     PubMed     Text format     Abstract available
     
     
     
208. HUANG H, Du T, Zhang Y, Lai Y, et al
     Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
     Prostate. 2017;77:718-728.
     PubMed     Text format     Abstract available
     
     
     
209. OLSON BM, Bradley ES, Sawicki T, Zhong W, et al
     Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).
     Prostate. 2017;77:812-821.
     PubMed     Text format     Abstract available
     
     
     
210. POMPE RS, Davis-Bondarenko H, Zaffuto E, Tian Z, et al
     Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
     Prostate. 2017;77:686-693.
     PubMed     Text format     Abstract available
     
     
     
211. MELITI A, Sadimin E, Diolombi M, Khani F, et al
     Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.
     Prostate. 2017;77:681-685.
     PubMed     Text format     Abstract available
     
     
     
212. PIERCONTI F, Martini M, Cenci T, Petrone GL, et al
     SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
     Prostate. 2017;77:597-603.
     PubMed     Text format     Abstract available
     
     
     
213. HENNING JD, Karamchandani JM, Bonachea LA, Bunker CH, et al
     Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
     Prostate. 2017;77:617-624.
     PubMed     Text format     Abstract available
     
     
     
214. BRETT SI, Lucien F, Guo C, Williams KC, et al
     Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples.
     Prostate. 2017;77:1335-1343.
     PubMed     Text format     Abstract available
     
     
     April 2017
215. SCHALLY AV, Block NL, Rick FG
     Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
     Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
     PubMed     Text format     Abstract available
     
     
     
216. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
     Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
     Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
     PubMed     Text format     Abstract available
     
     
     
217. JIA L, Gui B, Zheng D, Decker KF, et al
     Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
     Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
     PubMed     Text format     Abstract available
     
     
     
218. TANG B, Han CT, Gan HL, Zhang GM, et al
     Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
     Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
     PubMed     Text format     Abstract available
     
     
     
219. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
     Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
     Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
     PubMed     Text format     Abstract available
     
     
     
220. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
     When should active surveillance for prostate cancer stop if no progression is detected?
     Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
     PubMed     Text format     Abstract available
     
     
     
221. GONCALVES BF, de Campos SG, Goes RM, Scarano WR, et al
     Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone: Protective effect and emergence of unstable epithelial microenvironment.
     Prostate. 2017 Apr 12. doi: 10.1002/pros.23353.
     PubMed     Text format     Abstract available
     
     
     
222. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
     Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
     Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
     PubMed     Text format     Abstract available
     
     
     
223. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
     External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
     Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
     PubMed     Text format     Abstract available
     
     
     March 2017
224. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
     Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
     Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
     PubMed     Text format     Abstract available
     
     
     
225. HABL G, Sauter K, Schiller K, Dewes S, et al
     68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
     Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
     PubMed     Text format     Abstract available
     
     
     
226. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
     Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
     Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
     PubMed     Text format     Abstract available
     
     
     
227. TOLKACH Y, Eminaga O, Wotzel F, Huss S, et al
     Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.
     Prostate. 2017;77:396-405.
     PubMed     Text format     Abstract available
     
     
     November 2016
228. REGIS L, Planas J, Carles J, Maldonado X, et al
     Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
     Prostate. 2016 Nov 1. doi: 10.1002/pros.23256.
     PubMed     Text format     Abstract available
     
     
     July 2016
229. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
     Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
     Prostate. 2016;76:917-26.
     PubMed     Text format     Abstract available
     
     
     
230. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
     Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
     Prostate. 2016;76:905-16.
     PubMed     Text format     Abstract available
     
     
     June 2016
231. GERRIN SJ, Sowalsky AG, Balk SP, Ye H, et al
     Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma.
     Prostate. 2016 Jun 8. doi: 10.1002/pros.23212.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: